Robert Lisicki, EVP and Chief Commercial Officer of Arcutis Biotherapeutics, Inc., filed a Form 3 initial statement of beneficial ownership with the SEC on November 4, 2026, disclosing direct holdings in common stock and a stock option as of the event date of November 4, 2026.

Key Highlights

  • Reporting person: Robert Lisicki, identified as EVP, Chief Commercial Officer of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT).
  • Common stock: 55,000 restricted stock units (RSUs) beneficially owned directly, with vesting beginning August 17, 2027.
  • RSU vesting schedule: 25% of RSUs vest on each annual anniversary of August 17, 2026, subject to continued service.
  • Stock option: Option to purchase 145,000 shares of common stock at an exercise price of $25.61, expiring August 17, 2036.
  • Option vesting: Shares vest and become exercisable at 2.0833% per month from the vesting commencement date of August 17, 2026, subject to continued service.
  • Ownership form: Both the RSUs and the stock option are held directly.

Lisicki's Initial Beneficial Ownership at Arcutis Biotherapeutics

According to the filing, Robert Lisicki submitted a Form 3 as a newly reporting officer of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), with the date of event requiring the statement listed as November 4, 2026. Lisicki is identified in the filing as EVP, Chief Commercial Officer and filed as an individual reporting person. The form was signed by Latha Vairavan as attorney-in-fact for Robert Lisicki on November 4, 2026.

The filing discloses two securities positions. Under Table I, Lisicki reported direct beneficial ownership of 55,000 shares of common stock, described in the filing's footnotes as RSUs that will vest at the rate of 25% on each annual anniversary of August 17, 2026, beginning August 17, 2027, subject to continued service. Under Table II, the filing reports a stock option (right to buy) covering 145,000 shares of common stock, with an exercise price of $25.61 and an expiration date of August 17, 2036. According to the filing's explanation, these options vest at the rate of 2.0833% of shares on each monthly anniversary of August 17, 2026, subject to continued service through the applicable vesting date.

Both positions carry a vesting commencement date of August 17, 2026, as stated in the filing's explanations of responses. No indirect beneficial ownership was reported, and no amendments to a prior filing were indicated, consistent with this being an initial Form 3 submission.

What Was Disclosed

Arcutis Biotherapeutics EVP and Chief Commercial Officer Robert Lisicki filed an initial beneficial ownership statement reporting 55,000 RSUs and a stock option covering 145,000 shares at $25.61, both vesting from an August 17, 2026 commencement date.